A Phase 1/2 Study of TPX-0046, A Novel Oral RET/SRC Inhibitor in Adult Subjects With Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations
Latest Information Update: 17 Jun 2024
At a glance
- Drugs Enbezotinib (Primary)
- Indications Medullary thyroid cancer; Non-small cell lung cancer; Solid tumours; Thyroid cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms SWORD-1
- Sponsors Turning Point Therapeutics
Most Recent Events
- 14 Jun 2023 Status changed from active, no longer recruiting to discontinued (due to Adverse change in the risk/benefit).
- 09 Feb 2023 Planned End Date changed from 1 Nov 2026 to 1 Nov 2023.
- 09 Feb 2023 Planned primary completion date changed from 1 Dec 2025 to 1 Jul 2023.